Artelo Biosciences Inc ARTL 深 沪
等待开盘 03-27 09:30:00 美东时间
3.19
-1.660
-34.23%
华盛通- 最 高9.80
- 今 开2.955
- 成交量 212.50万股
- 最 低 1.05
- 昨 收 4.85
- 总市值 13.59万
- 52周最高 28.60
- 市盈率 静 --
- 换手率 4988.93%
- 52周最低 0.822
- 委 比 -72.80%
- 总股本 4.26万
- 历史最高 28.60
- 量 比 0.63
- 振 幅 180.41%
- 历史最低 0.26
- 每 手 1
- 风险率
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Artelo Biosciences Expands Into $16.3B Glaucoma Market Via Investigator‑Sponsored Study, Underscoring Multi‑Platform Pipeline Durability Across High‑Value Therapeutic Areas
Artelo Biosciences, Inc. (NASDAQ:ARTL) is drawing increased attention following its expansion into the $16.3 billion glaucoma market through a fully funded investigator-sponsored clinical study—an announcement that
03-25 19:34
Why Keysight Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
Shares of Keysight Technologies Inc (NYSE:KEYS) rose sharply in pre-market trad...
02-24 18:21
Artelo Biosciences Has Been Granted European Patent Number EP4259111 Titled "PHARMACEUTICAL COMPOSITIONS COMPRISING CANNABINOID AGONIST"
https://register.epo.org/application?number=EP21827629
2025-12-02 04:58
Maxim Group Downgrades Artelo Biosciences to Hold
Maxim Group analyst Jason McCarthy downgrades Artelo Biosciences (NASDAQ:ARTL) from Buy to Hold.
2025-11-19 23:48
Artelo Biosciences Announces Reverse Stock Split
Artelo Biosciences approves a 6-for-1 reverse stock split effective June 13, 2025, to increase share price and meet NASDAQ listing requirements.
2025-06-11 12:30
New Independent Review Paper Strengthens Therapeutic Rationale for Artelo’s FABP Inhibitor Program in Anxiety and Depression
Artelo Biosciences published a study highlighting the therapeutic potential of FABP inhibitors, particularly ART26.12, in treating anxiety, depression, and pain by targeting lipid signaling pathways. Clinical trials for ART26.12 are progressing with expected results this quarter.
2025-06-02 13:00
Artelo Biosciences盘中异动 下午盘快速下挫5.36%
北京时间2025年01月09日03时54分，Artelo Biosciences, Inc.（ARTL.us）股票出现波动，股价急速下跌5.36%。截至发稿，该股报1.09美元/股，成交量1.6728万股，换手率0.52%，振幅4.50%。 最近的财报数据显示，该股实现营业收入0.00美元，净利润-1.13百万美元，每股收益-0.35美元，毛利0.00美元，市盈率-0.39倍。 机构评级方面，在所有4家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。 Artelo Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.68%。其相关个股中，Sana ...
2025-01-09 03:54
